Hong Kong · Delayed Price · Currency is HKD TYK Medicines Company Description
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products.
Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation.
The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including breast cancer and prostate cancer; TY-2136b, an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor for the treatment of solid tumors; TY-2699a, a selective CDK7 inhibitor for the treatment of advanced/metastatic solid tumors; and TY-0540, a selective CDK2/4/6 inhibitor to treat advanced/metastatic solid tumors.
In addition, it develops TY-4028, an oral exon 20 insertion-TKI targeting locally advanced or metastatic NSCLC with EGFR exon 20 or HER2 exon 20 insertions; TY-1091, a potent and selective rearranged during transfection proto-oncogene (RET) inhibitor for the treatment of advanced NSCLC with RET gene fusion, advanced medullary thyroid cancer with RET gene mutation, and other advanced solid tumors with RET gene alterations; TY-1054, an oral yes associated protein-transcriptional enhanced associate domain inhibitor for cancer treatment; TY-1210, a selective CDK2 inhibitor to treat solid tumors; TY-0609, a selective CDK4 inhibitor for the treatment of cancer; and TY-3200, an EGFR degrader.
The company was incorporated in 2017 and is headquartered in Huzhou, China.
| Country | China |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 153 |
| CEO | Yusheng Wu |
Contact Details
Address: Tower A, Changxing World Trade Building Huzhou China | |
| Phone | 86 21 6167 6766 |
| Website | tykmedicines.com |
Stock Details
| Ticker Symbol | 2410 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100006L34 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yusheng Wu Ph.D. | Founder, Executive Chairman and Chief Executive Officer |
| Dr. Jun Li | Co-Founder and Non-Executive Director |
| Shaoqing Chen Ph.D. | Senior Vice President of Medicinal Chemistry Department |
| Xiugui Chen | Senior Vice President of Clinical and Registration Department |
| Wing Yee Wong | Company Secretary |